Literature DB >> 26332706

Regarding "True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo".

Joshua N Farr1, Shreyasee Amin1, Sundeep Khosla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26332706      PMCID： PMC4826036          DOI： 10.1002/jbmr.2700

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN： 0884-0431            Impact factor:   6.741


× No keyword cloud information.
  11 in total

Review 1.  Clinical practice. Postmenopausal osteoporosis.

Authors:  Clifford J Rosen
Journal:  N Engl J Med       Date:  2005-08-11       Impact factor: 91.245

Review 2.  Clinical practice. Osteopenia.

Authors:  Sundeep Khosla; L Joseph Melton
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

3.  Are the High Hip Fracture Rates Among Norwegian Women Explained by Impaired Bone Material Properties?

Authors:  Daysi Duarte Sosa; Laila Vilaplana; Roberto Güerri; Xavier Nogués; Morten Wang-Fagerland; Adolfo Diez-Perez; Erik F Eriksen
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

Review 4.  Type 2 diabetes and bone.

Authors:  William D Leslie; Mishaela R Rubin; Ann V Schwartz; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-09-28       Impact factor: 6.741

5.  A new device for performing reference point indentation without a reference probe.

Authors:  Daniel Bridges; Connor Randall; Paul K Hansma
Journal:  Rev Sci Instrum       Date:  2012-04       Impact factor: 1.523

6.  Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.

Authors:  Leonardo Mellibovsky; Daniel Prieto-Alhambra; Fernando Mellibovsky; Roberto Güerri-Fernández; Xavier Nogués; Connor Randall; Paul K Hansma; Adolfo Díez-Perez
Journal:  J Bone Miner Res       Date:  2015-06-11       Impact factor: 6.741

7.  Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density.

Authors:  Frank Malgo; Neveen A T Hamdy; Socrates E Papapoulos; Natasha M Appelman-Dijkstra
Journal:  J Clin Endocrinol Metab       Date:  2015-03-13       Impact factor: 5.958

8.  Cost-effective osteoporosis treatment thresholds: the United States perspective.

Authors:  A N A Tosteson; L J Melton; B Dawson-Hughes; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 9.  True Gold or Pyrite: A Review of Reference Point Indentation for Assessing Bone Mechanical Properties In Vivo.

Authors:  Matthew R Allen; Erin Mb McNerny; Jason M Organ; Joseph M Wallace
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

10.  Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

Authors:  Catherine MacLean; Sydne Newberry; Margaret Maglione; Maureen McMahon; Veena Ranganath; Marika Suttorp; Walter Mojica; Martha Timmer; Alicia Alexander; Melissa McNamara; Sheetal B Desai; Annie Zhou; Susan Chen; Jason Carter; Carlo Tringale; Di Valentine; Breanne Johnsen; Jennifer Grossman
Journal:  Ann Intern Med       Date:  2007-12-17       Impact factor: 25.391
View more
  3 in total

1.  Bone quality assessment techniques: geometric, compositional, and mechanical characterization from macroscale to nanoscale.

Authors:  Heather B Hunt; Eve Donnelly
Journal:  Clin Rev Bone Miner Metab       Date:  2016-08-22

2.  Microhardness distribution of the tibial diaphysis and test site selection for reference point indentation technique.

Authors:  Jianzhao Wang; Bing Yin; Guobin Liu; Sheng Li; Xiaojuan Zhang; Zusheng Hu; Weiwei Wu; Yingze Zhang
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

3.  Added Value of Impact Microindentation in the Evaluation of Bone Fragility: A Systematic Review of the Literature.

Authors:  Manuela Schoeb; Neveen A T Hamdy; Frank Malgo; Elizabeth M Winter; Natasha M Appelman-Dijkstra
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-07       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.